All In Biotech

Drug Trial Radar · NCT06685341

PK/PD Study of YZJ-1139

A Randomized, Double-Blind, Zolpidem and Placebo-Controlled, 4-Way-Period Crossover, Pharmacokinetics and Pharmacodynamics Study of YZJ-1139 Single-Dose Oral in Healthy Young and Elderly Chinese Subjects

Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Mar 7, 2019

Primary completion

Apr 10, 2019

Study completion Nov 15, 2019

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses. Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

Conditions

  • Insomnia

Interventions

  • YZJ-1139Drug

    YZJ-1139

  • PlaceboDrug

    Oral tablet

  • ZolpidemDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  2. AUCinf of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  3. AUClast of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  4. Tmax of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  5. t1/2 of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  6. CL/F of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  7. Vz/F of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  8. Left and right saccade peak velocity (SPV) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  9. left and right saccade accuracy rate (SacAcc) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  10. Left and right saccade eye movement response time (SacRT) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  11. Smooth eye movement to the left and right (Smooth) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  12. Body SwayTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  13. Simple response time of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  14. Simple response accuracy rate of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  15. Selective response time of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  16. Selective response accuracy rate of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  17. The average reaction time for correct responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  18. The number of correct responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  19. The average reaction time for incorrect responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  20. The number of incorrect responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  21. The number of non-responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  22. Immediate recall of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  23. Delayed recall of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
  24. Delayed recognition of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.